Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BMS-986036
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMS-986036 is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 02, 2018
Lead Product(s) : BMS-986036
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Bristol Myers Squibb
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emricasan
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Conatus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-17
Details : Emricasan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Liver Cirrhosis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2018
Lead Product(s) : Emricasan
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Conatus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Emricasan
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Undisclosed
Sponsor : Conatus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Companion Protocol for Methacetin Breath Test (MBT) in Conatus Protocol IDN-6556-14
Details : Emricasan is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 20, 2018
Lead Product(s) : Emricasan
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Undisclosed
Sponsor : Conatus Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Breathid Hp Lab System
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Urea Breath Test (UBT) With Breath Hp System /BreathID Hp Lab System Pediatrics
Details : Breathid Hp Lab System is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Helicobacter Infections.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
September 19, 2016
Lead Product(s) : Breathid Hp Lab System
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : 13-C Sodium Octanoate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI
Details : 13-C Sodium Octanoate is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Liver Diseases.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 13, 2011
Lead Product(s) : 13-C Sodium Octanoate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Toronto General Hospital | Medical University of South Carolina | Northwestern University | Henry Ford Health System | Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Benzoyl-L-Tyrosyl-Alanine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India
Deal Size : Inapplicable
Deal Type : Inapplicable
BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency
Details : Benzoyl-L-Tyrosyl-Alanine is a drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Pancreatitis, Chronic.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
December 14, 2010
Lead Product(s) : Benzoyl-L-Tyrosyl-Alanine
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Virginia Commonwealth University | Asian Institute of Gastroenterology, Hyderabad, India
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Caprylic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Recipient : Virginia Commonwealth University
Deal Size : Inapplicable
Deal Type : Inapplicable
Prediction of Severity of Liver Disease by a 13C Octanoate Breath Test (OBT)
Details : Sodium Octanoate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Metabolic Syndrome.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 19, 2010
Lead Product(s) : Caprylic Acid
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Recipient : Virginia Commonwealth University
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Grapefruit Juice
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II/ Phase III
Recipient : Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
¹³C-Methacetin Breath Test (MBT) Methodology Study
Details : Grapefruit Juice is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Liver Diseases.
Product Name : Undisclosed
Product Type : Plant Extract/Herbal
Upfront Cash : Inapplicable
September 20, 2010
Lead Product(s) : Grapefruit Juice
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II/ Phase III
Recipient : Hadassah Medical Organization
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
